On Oct. 9, 2003, a Canadian-led international clinical trial found that post-menopausal survivors of early-stage breast cancer who took the drug letrozole after completing an initial 5 years of tamoxifen therapy had a significantly reduced risk of cancer recurrence compared to women taking a placebo. The clinical trial had been halted early because of the positive results.